Почетна › Рак на бели дробови › Орегон
Клинички испитувања за Рак на бели дробови во Орегон
31 студии за Рак на бели дробови бараат учесници на локации во Орегон.
Градови во Орегон
Официјален текст на студијата (англиски)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Good Samaritan Hospital, Corvallis
- Three Rivers Community Hospital, Grants Pass
- Asante Rogue Regional Medical Center, Medford
- и уште 4
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- и уште 7
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Providence Portland Medical Center ( Site 0043), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0059), Portland
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07286149Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
Се регрутираФаза 3
Возраст 70 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Saint Charles Health System, Bend
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT04181060Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06498635Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Oncology Associates of Oregon PC, Eugene
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT06881784A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Portland
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07127874A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Oregon Health and Science University ( Site 0052), Portland
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Northwest Cancer Specialists, P.C, Happy Valley
- Northwest Cancer Specialists, P.C., Portland
- Northwest Cancer Specialists, P.C, Tigard
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07222566A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT06618287A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07063745Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07100080Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 10.9.2026 · NCT06293898A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Oregon Health and Science University, Portland
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Oncology Associates of Oregon, Eugene
- Asante Rogue Regional Medical Center, Medford
- Providence Portland Medical Center, Portland
- и уште 2
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06119581Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- USOR - Oncology Associates of Oregon, P.C, Eugene
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT06343402Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Legacy Mount Hood Medical Center, Gresham
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Legacy Meridian Park Hospital, Tualatin
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT05624996A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Providence Portland Medical Center, Portland
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 15.7.2026 · NCT05652686Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
- Willamette Valley Cancer Institute and Research Center, Eugene
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 9.7.2026 · NCT07315113Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Oregon Health and Science University, Portland
Се регрутираФаза 2
Возраст од 18 до 70 · Сите полови · Ажурирано 26.6.2026 · NCT04614103Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
- OHSU Knight Cancer Institute, Portland
Се регрутираФаза 4
Возраст 18 и постари · Сите полови · Ажурирано 12.6.2026 · NCT07405086Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Willamette Falls Medical Center, Oregon City
- и уште 4
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 3.6.2026 · NCT05642572MYLUNG Consortium Part 3: Observational Study
- Willamette Valley Cancer Institute and Research Center, Eugene
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 18.5.2026 · NCT05885698Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Willamette Falls Medical Center, Oregon City
- и уште 4
Се регрутираФаза 2
18 Minutes · Сите полови · Ажурирано 5.5.2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- и уште 5
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 5.5.2026 · NCT06616584cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст 40 и постари · Сите полови · Ажурирано 20.1.2026 · NCT05366881LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- и уште 1
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 9.1.2026 · NCT06073431SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 28.10.2025 · NCT03452774Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Oregon Health & Science University, Portland
Се регрутираНабљудувачка студија
Возраст 50 и постари · Сите полови · Ажурирано 5.8.2025 · NCT06122077Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.